Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MDT 
Medtronic PLC (MDT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/14/2025: MDT (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
32 Analysts rated it
Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.
1 Year Target Price $101.58
1 Year Target Price $101.58
| 12 | Strong Buy |
| 5 | Buy |
| 13 | Hold |
| 1 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -2.37% | Avg. Invested days 45 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/14/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 123.31B USD | Price to earnings Ratio 26.48 | 1Y Target Price 101.58 |
Price to earnings Ratio 26.48 | 1Y Target Price 101.58 | ||
Volume (30-day avg) 32 | Beta 0.74 | 52 Weeks Range 76.99 - 99.37 | Updated Date 11/16/2025 |
52 Weeks Range 76.99 - 99.37 | Updated Date 11/16/2025 | ||
Dividends yield (FY) 2.92% | Basic EPS (TTM) 3.62 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-18 | When Before Market | Estimate 1.31 | Actual - |
Profitability
Profit Margin 13.63% | Operating Margin (TTM) 18.69% |
Management Effectiveness
Return on Assets (TTM) 4.57% | Return on Equity (TTM) 9.74% |
Valuation
Trailing PE 26.48 | Forward PE 17.04 | Enterprise Value 143452396974 | Price to Sales(TTM) 3.61 |
Enterprise Value 143452396974 | Price to Sales(TTM) 3.61 | ||
Enterprise Value to Revenue 4.19 | Enterprise Value to EBITDA 15.35 | Shares Outstanding 1282616011 | Shares Floating 1280351394 |
Shares Outstanding 1282616011 | Shares Floating 1280351394 | ||
Percent Insiders 0.3 | Percent Institutions 87.85 |
Upturn AI SWOT
Medtronic PLC
Company Overview
History and Background
Medtronic was founded in 1949 as a medical equipment repair shop. It evolved into a medical technology company, pioneering implantable medical devices. Significant milestones include the development of the first wearable, battery-powered cardiac pacemaker in 1957 and numerous acquisitions expanding its product portfolio.
Core Business Areas
- Cardiovascular Portfolio: Develops and manufactures devices for cardiac rhythm management, coronary and peripheral vascular interventions, and structural heart therapies.
- Neuroscience Portfolio: Offers therapies for spinal and brain-related conditions, including neurostimulation, spinal implants, and surgical technologies.
- Medical Surgical Portfolio: Focuses on surgical technologies, including advanced energy, robotic surgery, and surgical navigation. It covers a range of procedures from minimally invasive to open surgeries.
- Diabetes Portfolio: Develops and commercializes insulin pumps, continuous glucose monitoring (CGM) systems, and related diabetes management solutions.
Leadership and Structure
The leadership team is headed by Geoff Martha (Chairman and CEO). The organizational structure is divided into the four core business portfolios listed above, each with its own president and management team. Corporate functions support these portfolios.
Top Products and Market Share
Key Offerings
- Description: Implantable devices that monitor and regulate heart rhythm, delivering electrical impulses as needed. Medtronic is a leading vendor in this market.
- Product Name 1: Pacemakers & ICDs: Devices that regulate heart rhythm. Market share fluctuates, but Medtronic is a major player. Competitors include Abbott (ABT), Boston Scientific (BSX), and Biotronik.
- Description: Insulin pumps and continuous glucose monitors (CGMs) help people with diabetes manage their blood sugar levels. Medtronic's MiniMed series is a key offering.
- Product Name 2: Insulin Pumps & CGMs: Devices for diabetes management. Competitors include Dexcom (DXCM), Insulet (PODD), and Abbott (ABT).
- Description: Offerings for spinal fusion, fracture repair, and other spinal procedures. Leading market share, but also a highly competitive field.
- Product Name 3: Spinal Implants: Devices for spinal surgery. Medtronic holds a significant market share. Competitors include Johnson & Johnson (JNJ) DePuy Synthes and Stryker (SYK)
Market Dynamics
Industry Overview
The medical device industry is characterized by innovation, regulation, and increasing demand due to an aging population and chronic diseases. Technology advancements and globalization are key trends.
Positioning
Medtronic is a leading medical technology company with a broad product portfolio and global reach. Its competitive advantages include its scale, established brand, innovation capabilities, and strong relationships with healthcare providers.
Total Addressable Market (TAM)
The global medical device market is expected to reach hundreds of billions of dollars. Medtronic is positioned to capture a significant portion of this TAM due to its diverse portfolio and market leadership. Expected to reach $600 billion by 2030. Medtronic is well positioned to capitalize on this TAM
Upturn SWOT Analysis
Strengths
- Broad product portfolio
- Global presence
- Strong brand reputation
- Significant R&D investment
- Established relationships with healthcare providers
Weaknesses
- Slow organic growth in some segments
- Exposure to pricing pressure
- Integration challenges with acquisitions
- Complex regulatory environment
- High debt levels
Opportunities
- Expanding into emerging markets
- Developing innovative technologies
- Acquiring complementary businesses
- Leveraging digital health solutions
- Addressing unmet medical needs
Threats
- Intense competition
- Regulatory changes
- Economic downturns
- Product recalls
- Healthcare cost containment
Competitors and Market Share
Key Competitors
- JNJ
- BSX
- ABT
- SYK
Competitive Landscape
Medtronic has the scale and resources to compete effectively, but faces challenges from innovative competitors and pricing pressures.
Major Acquisitions
Affera
- Year: 2022
- Acquisition Price (USD millions): 925
- Strategic Rationale: Expanded Medtronic's cardiac ablation portfolio, providing new technologies for treating atrial fibrillation.
Growth Trajectory and Initiatives
Historical Growth: Medtronic has grown through organic growth, acquisitions, and product innovation.
Future Projections: Analyst estimates for Medtronic's future growth can be found on financial websites and research reports.
Recent Initiatives: Recent initiatives may include new product launches, strategic partnerships, and restructuring efforts.
Summary
Medtronic is a strong medical technology company with a diverse product portfolio and global presence, but faces challenges related to organic growth, pricing pressure, and competition. Recent acquisitions and innovation efforts aim to drive future growth. Overall, Medtronic demonstrates financial strength, innovation in their offerings, and consistent shareholder returns. However, increased competition and a rapidly evolving market necessitates that Medtronic needs to stay ahead of the curve to retain its strong market share.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Medtronic Investor Relations
- SEC Filings
- Financial News Outlets
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data is approximate and may vary. Past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Medtronic PLC
Exchange NYSE | Headquaters - | ||
IPO Launch date 1978-01-13 | Chairman of the Board & CEO Mr. Geoffrey Straub Martha | ||
Sector Healthcare | Industry Medical Devices | Full time employees 95000 | Website https://www.medtronic.com |
Full time employees 95000 | Website https://www.medtronic.com | ||
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems and sensors, and InPen, a smart insulin pen. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.